About Biquelle2020-03-23T15:50:47+00:00


About Biquelle XL

Welcome to biquelle.co.uk

Biquelle XL is a prolonged-release tablet of quetiapine indicated for the:1

  • Treatment of schizophrenia;

  • Treatment of moderate to severe manic and major depressive episodes in bipolar disorder;

  • Prevention of recurrence of manic or depressive episodes in patients with bipolar disorder who have previously responded to quetiapine;

  • Treatment of major depressive episodes in patients with Major Depressive Disorder who have had sub-optimal response to antidepressant monotherapy as an add-on treatment.

Available as:

  • 50mg prolonged-release tablets

  • 150mg prolonged-release tablets

  • 200mg prolonged-release tablets

  • 300mg prolonged-release tablets

  • 400mg prolonged-release tablets

Biquelle XL is bioequivalent to Seroquel (quetiapine) XL tablets (AstraZeneca, London, UK).2

Biquelle XL could offer significant cost savings to your practice and clinical commissioning group (CCG).

Quetiapine 50mg, 150mg, 200mg, 300mg and 400mg prolonged-release tablets are in category C of the UK Drug Tariff.3

However, the NHS can make 56% savings on the cost of category C quetiapine by prescribing Biquelle XL by brand name.3*

Quite simply a wholesale switch of quetiapine 50mg, 150mg, 200mg, 300mg and 400mg prolonged-release prescriptions to Biquelle XL could still save an average CCG £40,612 per year.4**

Biquelle XL is one of Aspire Pharma’s cost saving prolonged-release products.

In addition, Biquelle XL:

  • Full range of strengths available for Biquelle XL;

  • Available from mainline wholesalers;

  • High level of stockholdings;

  • Bioequivalent to the originator brand;2

  • Price guaranteed***

*56% saving on the cost of Category C quetiapine prolonged-release tablets in the UK Drug Tariff. ** Potential still to save based on the market data in reference 4 for 218 CCGs switching their generic and brand originator quetiapine prolonged-release tablet prescriptions to Biquelle XL. ***No change in price subject to no material change to the products or Category C of the UK Drug Tariff until the 2024 PPRS review.
References: 1) Biquelle XL SmPCs. 2) Data on file. 1010067149 v 4.0 October 2019. 3) February 2020 UK Drug Tariff. 4) epact data November 2018 – November 2019 (England, Wales , NI )
For further information please call: 01730 231148,
email: info@aspirepharma.co.uk or visit www.aspirepharma.co.uk
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148

For more information about Biquelle XL, please see the abbreviated prescribing information.

Revision reference – Biquelle XL_16_23.03.2020

More products available
in this range:
Click to view their
individual websites